In silico modelling of thymoquinone disruption of PCSK9-LDLR binding for cholesterol regulation

Simple item page
dc.contributor.authorSirimanne, N. L
dc.contributor.authorRodrigo,U. A. A
dc.contributor.authorJayakody, R.S
dc.date.accessioned2026-09-30T08:14:06Z
dc.date.available2026-09-30T08:14:06Z
dc.date.issued2026-05-02
dc.descriptionAbstract No: 2025_425 Page No 88
dc.description.abstractCardiovascular disease remains a leading cause of global mortality, with hypercholesterolemia identified as a major modifiable risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol by binding to the EGF-A domain of the low-density lipoprotein receptor (LDLR), promoting its degradation and thereby reducing LDL-cholesterol clearance.
dc.identifier.issn1012-8999
dc.identifier.urihttps://dr.ichemc.ac.lk/handle/123456789/551
dc.language.isoen
dc.publisherInstitute Of Chemistry Ceylon
dc.relation.ispartofseries43 ; 2
dc.subjectThymoquinone
dc.subjectPCSK9
dc.subjectLDLR
dc.subjectmolecular docking
dc.subjectmolecular dynamics
dc.titleIn silico modelling of thymoquinone disruption of PCSK9-LDLR binding for cholesterol regulation
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
In silico modelling of thymoquinone disruption of PCSK9-LDLR binding.pdf
Size:
650.73 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Abstract